A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions
Background: Flurbiprofen 8.75 mg lozenges and oromucosal sprays are used for symptomatic relief of sore throat in patients aged 12 years and over. The documented adverse events of flurbiprofen use include those related to its pharmacological actions, namely, increased risk of haemorrhagic events, ho...
Main Authors: | Alison Evans, Debabrata Roy, Sandeep Dhanda, Samantha Lane, Graça Coutinho, Anuradha Kulasekaran, David Miller-Shakesby, Nagalakshmi Ramamoorthi, Saad Shakir |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1107185/full |
Similar Items
-
Relationship between Pharmacokinetic Profile and Clinical Efficacy Data of Three Different Forms of Locally Applied Flurbiprofen in the Mouth/Throat
by: Vit Perlik, et al.
Published: (2023-07-01) -
Flurbiprofen-Loaded Solid SNEDDS Preconcentrate for the Enhanced Solubility, In-Vitro Dissolution and Bioavailability in Rats
by: Rae Man Kim, et al.
Published: (2018-11-01) -
Postoperative short-term use of the nonsteroidal anti-inflammatory drug flurbiprofen did not increase the anastomotic leakage rate in patients undergoing elective gastrointestinal surgery—a retrospective cohort study
by: Huang Nie, et al.
Published: (2022-08-01) -
Patches as Polymeric Systems for Improved Delivery of Topical Corticosteroids: Advances and Future Perspectives
by: Natallia V. Dubashynskaya, et al.
Published: (2022-10-01) -
Diagnosis and treatment of flurbiprofen‐induced Stevens–Johnson syndrome: A rare case report
by: Asad Ali Khan, et al.
Published: (2022-09-01)